Cargando…

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects

INTRODUCTION: Pyroglutamate-amyloid-β (pE-Aβ) peptides are major components of Aβ-oligomers and Aβ-plaques, which are regarded as key culprits of Alzheimer's disease (AD) pathology. PQ912 is a competitive inhibitor of the enzyme glutaminyl cyclase (QC), essential for the formation of pE-Aβ pept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lues, Inge, Weber, Frank, Meyer, Antje, Bühring, Uli, Hoffmann, Torsten, Kühn-Wache, Kerstin, Manhart, Susanne, Heiser, Ulrich, Pokorny, Rolf, Chiesa, Joseph, Glund, Konrad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975062/ https://www.ncbi.nlm.nih.gov/pubmed/29854937 http://dx.doi.org/10.1016/j.trci.2015.08.002

Ejemplares similares

Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
por: Hoffmann, Torsten, et al.
Publicado: (2021)

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
por: Scheltens, Philip, et al.
Publicado: (2018)

Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD
por: Vijverberg, E. G. B., et al.
Publicado: (2021)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease
por: Kanemitsu, Naotoshi, et al.
Publicado: (2021)

Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2018)

Soluble Variants of Human Recombinant Glutaminyl Cyclase
por: Castaldo, Cristiana, et al.
Publicado: (2013)

In vitro and in silico determination of glutaminyl cyclase inhibitors
por: Tran, Phuong-Thao, et al.
Publicado: (2019)

The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions
por: Cynis, Holger, et al.
Publicado: (2011)

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration
por: Becker, Andreas, et al.
Publicado: (2013)

Identification of Glutaminyl Cyclase Genes Involved in Pyroglutamate Modification of Fungal Lignocellulolytic Enzymes
por: Wu, Vincent W., et al.
Publicado: (2017)

A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2021)

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells
por: Shang, Qi, et al.
Publicado: (2022)

The Bacteroidetes Q-rule and glutaminyl cyclase activity increase the stability of extracytoplasmic proteins
por: Szczęśniak, Katarzyna, et al.
Publicado: (2023)

Tetrahydroimidazo[4,5-c]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase
por: Ramsbeck, Daniel, et al.
Publicado: (2021)

Malaria parasite evades mosquito immunity by glutaminyl cyclase–mediated posttranslational protein modification
por: Kolli, Surendra Kumar, et al.
Publicado: (2022)

Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site
por: Booth, Rachell E, et al.
Publicado: (2004)

Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy
por: Gillis, John Stuart
Publicado: (2006)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors
por: Hielscher-Michael, Stephanie, et al.
Publicado: (2016)

Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis
por: Taudte, Nadine, et al.
Publicado: (2021)

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease
por: Chen, Daoyuan, et al.
Publicado: (2023)

40 912 km
Publicado: (2020)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

Disturbed Ca(2+) Homeostasis Increases Glutaminyl Cyclase Expression; Connecting Two Early Pathogenic Events in Alzheimer’s Disease In Vitro
por: De Kimpe, Line, et al.
Publicado: (2012)

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2011)

Linked Production of Pyroglutamate-Modified Proteins via Self-Cleavage of Fusion Tags with TEV Protease and Autonomous N-Terminal Cyclization with Glutaminyl Cyclase In Vivo
por: Shih, Yan-Ping, et al.
Publicado: (2014)

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions
por: Baumann, Niklas, et al.
Publicado: (2021)

Distinct glutaminyl cyclase expression in Edinger–Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Aβ pathology in Alzheimer’s disease
por: Morawski, Markus, et al.
Publicado: (2010)

D'Amour, P.Q.; roman /
por: Godbout, Jacques, 1933-
Publicado: (1972)

PQ, a new program for phylogeny reconstruction
por: Penzar, Dmitry, et al.
Publicado: (2018)

Rural arts entrepreneurs’ placemaking – how ‘entrepreneurial placemaking’ explains rural creative hub evolution during COVID-19 lockdown
por: Hill, Inge, et al.
Publicado: (2021)

Structural conservation of an ancient tRNA sensor in eukaryotic glutaminyl-tRNA synthetase
por: Grant, Thomas D., et al.
Publicado: (2012)

Effect of 9,12-Octadecadiynoic Acid on Neurobehavioral Development in Caenorhabditis elegans
por: Chen, Tun-Chieh, et al.
Publicado: (2021)

912. Influence of a Global Pandemic on Bronchiolitis at a Bronx Hospital
por: Rosenberg, Michael, et al.
Publicado: (2023)

Rational design and directed evolution of a bacterial-type glutaminyl-tRNA synthetase precursor
por: Guo, Li-Tao, et al.
Publicado: (2012)

Production of sigmao in sqrt (s) = 91.2 GeV qqbar events at LEP
por: Legan, Christopher Kenneth
Publicado: (1997)

912. Expansion of Hepatitis C Treatment with New Medicaid Subscription Model in Louisiana
por: Richey, Lauren E, et al.
Publicado: (2021)

P912: COVID19 SEVERITY AND THERAPEUTIC OPTIONS IN PATIENTS WITH MULTIPLE MYELOMA
por: Karimova, E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s3d84lvpo719p6vguv5oiu873j